U.S. Diversified Financial Stock News

Federated Hermes, NYSE:FHI, has received board approval to establish a new office in Hong Kong. The expansion is aimed at serving major financial institutions across Asia more directly. The move marks a material shift in the company’s geographic footprint beyond its existing bases. Federated Hermes, trading at $53.03, is extending its reach into Asia with a Hong Kong office aimed at deepening relationships with large financial institutions. The company has delivered a 37.4% return over the...

Coastal Financial CEO executes an open market sale of company shares under a Rule 10b5-1 trading plan. The transaction involves pre arranged selling activity by an insider at NasdaqGS:CCB. The move attracts attention as investors review what it may signal about leadership and capital allocation. For context, Coastal Financial, trading on NasdaqGS:CCB, last closed at $100.81. The stock has seen a 12.1% gain over the past year, alongside very large returns over the past 5 years. More...

If you are wondering whether Figma's share price lines up with its real worth, this article will walk through what the numbers are actually saying about valuation. The stock last closed at US$27.07, with returns of a 4.8% decline over 7 days and a 28.1% decline over 30 days, which may have changed how some investors see its risk and potential reward. Recent coverage around Figma has focused on its position in collaborative design software and how investors are weighing that against the...

MarineMax (HZO) opened Q1 2026 with revenue of US$505.2 million and a basic EPS loss of US$0.36, compared with Q1 2025 revenue of US$468.5 million and EPS of US$0.80. Over the intervening quarters, revenue ranged between roughly US$552 million and US$657.2 million. EPS moved from a profit of US$0.15 in Q2 2025 to a larger loss of US$2.42 in Q3 2025, keeping margin pressure firmly in focus for investors trying to make sense of the latest print. See our full analysis for MarineMax. With the...

AbCellera Biologics (NasdaqGS:ABCL) has begun dosing patients in the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635. ABCL635 is a non hormonal candidate for treating moderate to severe vasomotor symptoms associated with menopause. This Phase 2 dosing milestone marks further clinical progress in the company's efforts to develop a potential first in class menopause therapy. AbCellera Biologics, known for its antibody discovery platform, is pushing deeper into clinical development...

TFS Financial Corporation recently reported past first-quarter results for the period ended December 31, 2025, with net interest income rising to US$75.68 million while net income held roughly steady at US$22.27 million, or US$0.08 per share. Beneath the stable earnings per share, the company is contending with pressure on net interest margins and higher non-interest costs linked to bonuses, marketing, and technology spending, even as management points to strong capital and credit...

If you are wondering whether Winnebago Industries is a bargain or a value trap at around US$46.65 per share, this breakdown will help you frame that question with actual numbers. The stock is roughly flat over the last year with a 0.2% return. It shows a 13.4% gain over the past 30 days and a 3.8% decline over the last week, alongside longer term 3 year and 5 year returns of 25.8% and 25.4% declines. Recent moves in the share price sit against a backdrop of ongoing interest in RV and outdoor...

Nurix Therapeutics (NRIX) closed out FY 2025 with Q4 revenue of US$13.6 million and a basic EPS loss of US$0.82, while the trailing twelve months show revenue of US$84.0 million and a basic EPS loss of US$3.05. Over recent periods, the company has seen quarterly revenue range from US$7.9 million to US$44.1 million and basic EPS losses move between US$0.52 and US$1.03 per quarter. This sets the backdrop for what remains an early stage, loss making biotech story. For investors, the key question...

Wondering whether Extreme Networks is priced attractively today or if the recent share moves are a warning sign? This article focuses squarely on what you are getting for the current price. The stock last closed at US$14.37, with returns of a 5.4% decline over the past week, a 14.9% decline over the last month, and a 13.1% decline year to date. The 1 year return is a 7.9% decline and the 3 year return is a 23.6% decline, compared with a 5 year return of 61.1%. Recent attention around Extreme...

Ziff Davis (NasdaqGS:ZD) has launched the unified RetailMeNot Group, bringing several of its shopping platforms under one banner. The new group introduces AI powered tools designed to improve the online shopping experience for consumers. This move reflects Ziff Davis's focus on digital retail and customer engagement through technology. Ziff Davis, through RetailMeNot Group, is leaning further into digital retail and online deal discovery, an area where consumer expectations for...

Brookfield Infrastructure Partners' FY 2025 Earnings Snapshot Brookfield Infrastructure Partners (NYSE:BIP) closed out FY 2025 with fourth quarter revenue of about US$6.3 billion, basic EPS of US$0.40 and net income of US$245 million, putting a spotlight on how its profitability is tracking against expectations. The company has seen revenue move from US$5.4 billion in Q4 2024 to roughly US$6.3 billion in Q4 2025, while basic EPS shifted from US$0.26 to US$0.40 over the same period. This gives...

CONMED (CNMD) just wrapped up FY 2025 with Q4 revenue of US$373.2 million and basic EPS of US$0.54, alongside trailing twelve month revenue of about US$1.4 billion and EPS of US$1.52. Over the past six quarters in the dataset, revenue has ranged from US$316.7 million to US$373.2 million per quarter, while quarterly EPS has moved between US$0.09 and US$1.59. With trailing net margin sitting at 3.4% versus 10.1% a year earlier, this latest result puts a clear focus on how sustainable the...

Royal Caribbean Cruises (RCL) has just posted its FY 2025 numbers, with fourth quarter revenue at US$4.3b and basic EPS of US$2.78, capping a trailing twelve month run of US$17.9b in revenue and US$15.75 in EPS. Over recent periods the company has seen quarterly revenue move from US$3.8b and EPS of US$2.05 in Q4 2024 to US$5.1b and EPS of US$5.79 in Q3 2025, before this latest quarter. This sets up the full year against a backdrop of faster earnings growth than revenue and meaningfully higher...

Regencell Bioscience Holdings (RGC) is back in focus after recent coverage highlighted a sharp surge in its market value, despite having no revenue, recurring losses, and an ongoing Justice Department investigation. See our latest analysis for Regencell Bioscience Holdings. The share price has been volatile, with a 1 day share price return of a 13.61% decline and a 7 day share price return of a 9.34% decline. Despite this, it still sits on a 30 day share price return of 21.81% and a 90 day...

V.F. Corporation (VFC) just posted Q3 2026 results with revenue of US$2.9b and basic EPS of US$0.77, setting a clear reference point for how the year is shaping up. The company has seen quarterly revenue move from US$2.8b in Q2 2026 and US$2.9b in Q3 2025, while EPS shifted from US$0.49 in Q2 2026 and US$0.43 in Q3 2025, giving investors a clean view of how the income statement is trending as margins settle after a volatile period. See our full analysis for V.F. With the latest numbers on the...

Multiple major analysts upgraded KLA (NasdaqGS:KLAC), citing strong demand for advanced semiconductor inspection equipment and growth in 2nm process technology. KLA reported significantly improved quarterly financial results, with revenue and profit both moving higher. The combination of analyst upgrades and the latest earnings release has sharpened investor focus on KLA's role in next generation chip manufacturing. KLA enters this news cycle with its share price at $1,684.71 and a very...

Third Point has escalated its activist campaign at CoStar Group, pushing for a board overhaul and fresh directors at NasdaqGS:CSGP. The fund is urging CoStar to refocus on its core commercial real estate data business and consider divesting its residential real estate operations. Third Point has publicly criticized governance, strategy, and management compensation, framing its campaign as an effort to restore shareholder value. For shareholders, this fight comes after a challenging run for...

In late January 2026, Texas Instruments reported full-year 2025 sales of US$17.68 billion and net income of US$5.00 billion, while issuing first-quarter 2026 guidance for revenue of US$4.32 billion to US$4.68 billion and earnings per share of US$1.22 to US$1.48. Management highlighted rapidly expanding data center and recovering industrial demand, areas that now meaningfully contribute to Texas Instruments’ analog and embedded processing business mix and future focus. We’ll now examine how...

EchoStar investors are reacting to reports of a potential merger between SpaceX and xAI. The focus is on how any restructuring or reprioritization at SpaceX could affect EchoStar's investment exposure. The situation introduces fresh uncertainty around future benefits or risks to EchoStar tied to its SpaceX position. For you as an EchoStar shareholder, the key issue is how tightly the company is linked to SpaceX at a time when a potential merger with xAI is being discussed. EchoStar, trading...

If you are wondering whether QuidelOrtho at around US$27.41 is a potential value opportunity or a value trap, you are in the right place. The stock has had a weak run, with a 10.3% decline over the last 7 days, a 6.5% decline over 30 days, a 4.8% decline year to date, and a 36.5% decline over the last year, building on much larger 3 year and 5 year declines of 70.0% and 88.0%. Recent coverage has focused on QuidelOrtho's position in the broader healthcare and diagnostics space and how...

A senior executive at Employers Holdings (EIG) recently bought shares, and the stock has moved above a widely watched long term moving average. These developments are attracting fresh attention from investors tracking sentiment and trend signals. See our latest analysis for Employers Holdings. That insider purchase and move above a long term average comes after a 90 day share price return of 17.23% and a 5 year total shareholder return of 71.83%, suggesting momentum has picked up recently...

If you are wondering whether Applied Industrial Technologies is attractively priced right now, the recent share performance gives you a useful starting point but not the full story. The stock last closed at US$259.51, with returns of an 8.1% decline over 7 days, a 0.6% decline over 30 days, broadly flat year to date, a 0.8% decline over 1 year, 82.2% over 3 years and 248.6% over 5 years. These mixed shorter term moves, set against much stronger multi year returns, have put valuation in...

If you are wondering whether First American Financial at around US$64.06 is offering good value or asking too much, you are in the right place for a clear look at what the current price really implies. The stock has seen a 1.5% decline over the last 7 days, while returns over 30 days, year to date, 1 year, 3 years and 5 years stand at 3.2%, 4.9%, 3.9%, 11.7% and 39.5% respectively. This gives some context for how the market has been reassessing it over different time frames. Recent coverage...

If you are wondering whether Atmos Energy at around US$166 is still a sensible entry or hold for you, the key question is how that price compares with the company’s underlying value. The stock has been relatively steady in the short term, with a 0.4% return over the last 7 days and a 1.5% decline over the last 30 days. The 1 year and 5 year returns of 18.9% and 112.1% provide a longer track record that many investors will be thinking about. Recent news coverage has largely focused on Atmos...